meclozine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
diphenylmethyl piperazine derivatives 1649 569-65-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • meclizine
  • meclizine hydrochloride
  • meclozine
  • meclozine dihydrochloride
  • meclizine HCl
A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.
  • Molecular weight: 390.96
  • Formula: C25H27ClN2
  • CLOGP: 6.73
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -5.58
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
50 mg O
50 mg R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
S (Water solubility) 0.26 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 5.214 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.887 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.347 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 17.022 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 0.110 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 0.140 % High 1
herg hERG pIC50 5.387 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 12.359 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 77.446 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 0.140 % High 1
kinase-selectivity-class AKT3,AXL,ERBB2,GRK2,SIK2 5
kinase-safety-class ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TTK 42
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.024 High 1
mh-clint Mouse hepatocyte intrinsic clearance 95.060 High 1
mppb Mouse plasma protein binding (% unbound) 0.140 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.065 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
pppb Pig plasma protein binding (% unbound) 0.260 % High 1
rh-clint Rat hepatocyte intrinsic clearance 86.896 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 0.340 % High 1
rppb Rat plasma protein binding (% unbound) 0.120 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 0.166 uM High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 14, 1957 FDA CITRON PHARMA LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vertigo 209.21 11.56 171 27058 69640 90531578
Dizziness 127.12 11.56 427 26802 588857 90012361
Pemphigus 84.91 11.56 3 27226 326861 90274357
Fall 83.21 11.56 325 26904 481485 90119733
Hand deformity 76.01 11.56 3 27226 296359 90304859
Contraindicated product administered 73.69 11.56 6 27223 320133 90281085
Synovitis 71.09 11.56 8 27221 329744 90271474
Multiple sclerosis relapse 65.98 11.56 80 27149 52225 90548993
Systemic lupus erythematosus 64.18 11.56 15 27214 361881 90239337
Infusion related reaction 63.44 11.56 23 27206 416757 90184461
Pericarditis 62.34 11.56 5 27224 270146 90331072
Anti-cyclic citrullinated peptide antibody positive 58.63 11.56 3 27226 236430 90364788
Maternal exposure during pregnancy 58.05 11.56 18 27211 360045 90241173
Glossodynia 57.72 11.56 13 27216 321766 90279452
Helicobacter infection 55.87 11.56 3 27226 226847 90374371
Cerebrovascular accident 54.57 11.56 117 27112 123416 90477802
Lower respiratory tract infection 54.22 11.56 6 27223 250653 90350565
Drug ineffective 53.35 11.56 225 27004 1384073 89217145
Treatment failure 53.09 11.56 13 27216 303915 90297303
Product dose omission issue 49.62 11.56 196 27033 291491 90309727
Hepatic enzyme increased 48.33 11.56 24 27205 360712 90240506
Dysphoria 47.25 11.56 27 27202 6127 90595091
Folliculitis 46.53 11.56 4 27225 204349 90396869
Urticaria thermal 44.32 11.56 13 27216 520 90600698
Arthropathy 43.84 11.56 28 27201 366214 90235004
Transient ischaemic attack 43.38 11.56 59 27170 43117 90558101
General physical health deterioration 42.71 11.56 27 27202 355088 90246130
Completed suicide 42.22 11.56 117 27112 144941 90456277
Salivary gland calculus 40.87 11.56 10 27219 197 90601021
Rheumatoid factor positive 40.08 11.56 3 27226 171647 90429571
Liver injury 39.78 11.56 3 27226 170564 90430654
Appetite disorder 37.49 11.56 27 27202 9106 90592112
Femoral neck fracture 36.94 11.56 28 27201 10205 90591013
Asthenia 36.69 11.56 280 26949 533471 90067747
Urinary tract infection 36.57 11.56 185 27044 305447 90295771
Multiple sclerosis 35.79 11.56 43 27186 27797 90573421
Impaired healing 35.47 11.56 13 27216 234186 90367032
Balance disorder 34.08 11.56 84 27145 96996 90504222
Administration site erythema 33.67 11.56 12 27217 897 90600321
Gait disturbance 33.52 11.56 161 27068 260335 90340883
Inflammation 32.44 11.56 7 27222 178585 90422633
Illness 32.09 11.56 74 27155 81895 90519323
Tremor 31.95 11.56 110 27119 153063 90448155
Wound 31.29 11.56 27 27202 302953 90298265
Visual impairment 31.13 11.56 99 27130 132266 90468952
Nausea 30.52 11.56 485 26744 1109831 89491387
Off label use 30.12 11.56 201 27028 1102051 89499167
Feeling abnormal 29.72 11.56 114 27115 167121 90434097
Dizziness postural 28.83 11.56 23 27206 9030 90592188
Vitamin B12 deficiency 28.17 11.56 21 27208 7465 90593753
Swelling 28.02 11.56 52 27177 419006 90182212
Type 2 diabetes mellitus 28.00 11.56 13 27216 203231 90397987
Psoriatic arthropathy 27.93 11.56 17 27212 228318 90372900
Drug intolerance 27.81 11.56 58 27171 447533 90153685
Photophobia 27.58 11.56 33 27196 21236 90579982
C-reactive protein increased 27.58 11.56 10 27219 181379 90419839
Congenital hypoplasia of depressor angularis oris muscle 27.00 11.56 6 27223 76 90601142
Chills 26.84 11.56 94 27135 131887 90469331
Ill-defined disorder 26.77 11.56 11 27218 184880 90416338
Haemorrhagic diathesis 26.57 11.56 18 27211 5506 90595712
Back pain 26.17 11.56 174 27055 317001 90284217
Joint swelling 25.90 11.56 72 27157 503228 90097990
Headache 25.62 11.56 382 26847 862364 89738854
Coronary artery disease 25.17 11.56 40 27189 33583 90567635
Pyrexia 24.89 11.56 108 27121 660377 89940841
Dehydration 24.87 11.56 120 27109 194327 90406891
Somnolence neonatal 24.72 11.56 6 27223 114 90601104
Oral pain 24.62 11.56 39 27190 32644 90568574
Discomfort 24.25 11.56 28 27201 274307 90326911
Constipation 23.84 11.56 155 27074 280240 90320978
Thinking abnormal 23.67 11.56 23 27206 11709 90589509
Fatigue 23.51 11.56 481 26748 1153542 89447676
Skin warm 23.36 11.56 19 27210 7668 90593550
Infantile apnoea 22.92 11.56 10 27219 1277 90599941
Arthritis infective 22.71 11.56 19 27210 7973 90593245
Cardiac failure congestive 22.45 11.56 73 27156 98621 90502597
Irritable bowel syndrome 22.01 11.56 18 27211 207430 90393788
Wound infection 21.89 11.56 3 27226 106399 90494819
Seizure 21.58 11.56 97 27132 152532 90448686
Chest pain 21.53 11.56 167 27062 319478 90281740
Stomatitis 21.23 11.56 31 27198 274667 90326551
Inner ear disorder 21.10 11.56 8 27221 712 90600506
Anxiety 20.95 11.56 162 27067 309610 90291608
Sialoadenitis 20.68 11.56 11 27218 2171 90599047
Bursitis 20.45 11.56 7 27222 131647 90469571
Pre-existing condition improved 20.45 11.56 19 27210 9150 90592068
Tinnitus 20.38 11.56 42 27187 43060 90558158
Exposure during pregnancy 20.35 11.56 25 27204 238385 90362833
Myalgia 20.22 11.56 105 27124 175020 90426198
COVID-19 20.02 11.56 102 27127 168741 90432477
Facet joint syndrome 19.71 11.56 3 27226 98386 90502832
Fibromyalgia 19.39 11.56 20 27209 206249 90394969
Decerebrate posture 19.15 11.56 5 27224 129 90601089
Full blood count decreased 19.10 11.56 33 27196 29656 90571562
Pigmentation disorder 18.70 11.56 15 27214 5934 90595284
Delusional disorder, persecutory type 18.70 11.56 6 27223 325 90600893
Mobility decreased 18.69 11.56 29 27200 250705 90350513
Vision blurred 18.62 11.56 74 27155 110219 90490999
Condition aggravated 18.06 11.56 105 27124 595440 90005778
Bronchitis 17.86 11.56 92 27137 152835 90448383
Febrile neutropenia 17.73 11.56 13 27216 158336 90442882
Loss of consciousness 17.53 11.56 86 27143 140152 90461066
Sleep apnoea syndrome 17.51 11.56 33 27196 31714 90569504
Blood potassium decreased 17.49 11.56 42 27187 47685 90553533
Scratch 17.44 11.56 18 27211 9848 90591370
Cough 17.23 11.56 178 27051 368784 90232434
Rhinorrhoea 17.18 11.56 62 27167 88254 90512964
Syncope 17.05 11.56 82 27147 132581 90468637
Macrocephaly 16.83 11.56 5 27224 209 90601009
Skin disorder 16.46 11.56 35 27194 36671 90564547
Sneezing 16.41 11.56 31 27198 29838 90571380
Therapeutic product effect decreased 16.37 11.56 37 27192 277534 90323684
Dysphagia 16.35 11.56 72 27157 112206 90489012
Myocardial infarction 16.23 11.56 69 27160 105903 90495315
Hallucination 16.11 11.56 50 27179 65909 90535309
Hypomagnesaemia 16.04 11.56 34 27195 35554 90565664
Depression 15.98 11.56 149 27080 300452 90300766
Intentional dose omission 15.92 11.56 23 27206 17760 90583458
Urinary incontinence 15.91 11.56 35 27194 37531 90563687
Nervousness 15.88 11.56 33 27196 34023 90567195
Neck pain 15.78 11.56 72 27157 113891 90487327
Accidental death 15.76 11.56 9 27220 2039 90599179
Thrombocytopenia 15.69 11.56 24 27205 208701 90392517
Multiple allergies 15.67 11.56 21 27208 15125 90586093
Product use issue 15.65 11.56 49 27180 329870 90271348
Joint range of motion decreased 15.36 11.56 11 27218 135632 90465586
Influenza 15.04 11.56 82 27147 139182 90462036
Therapeutic product effect incomplete 14.86 11.56 22 27207 193874 90407344
Lung disorder 14.69 11.56 14 27215 149869 90451349
Alopecia 14.62 11.56 88 27141 494983 90106235
Floppy infant 14.50 11.56 4 27225 128 90601090
Diverticulum 14.42 11.56 18 27211 12095 90589123
Hypersensitivity 14.40 11.56 79 27150 454598 90146620
Dyspnoea 14.36 11.56 356 26873 880599 89720619
Grip strength decreased 14.24 11.56 5 27224 92571 90508647
Patient isolation 14.24 11.56 3 27226 29 90601189
Migraine 14.23 11.56 102 27127 190290 90410928
Hospice care 14.16 11.56 16 27213 9688 90591530
Drug interaction 13.87 11.56 40 27189 276413 90324805
Peripheral venous disease 13.86 11.56 4 27225 83917 90517301
Prescribed overdose 13.82 11.56 6 27223 97619 90503599
Rheumatoid arthritis 13.81 11.56 59 27170 362555 90238663
Cardiac disorder 13.78 11.56 43 27186 56829 90544389
Diarrhoea 13.41 11.56 373 26856 938817 89662401
Retroplacental haematoma 13.25 11.56 4 27225 177 90601041
Neutropenia 13.24 11.56 30 27199 224874 90376344
Dry skin 13.22 11.56 57 27172 88016 90513202
Head injury 13.14 11.56 29 27200 31159 90570059
Tenderness 12.49 11.56 26 27203 26842 90574376
Stress 12.46 11.56 53 27176 81342 90519876
Dementia Alzheimer's type 12.26 11.56 6 27223 995 90600223
Skin plaque 12.16 11.56 15 27214 9960 90591258
Deafness permanent 12.12 11.56 5 27224 556 90600662
Neck injury 11.88 11.56 8 27221 2424 90598794
Haematoma 11.85 11.56 32 27197 39016 90562202
Peripheral vascular disorder 11.85 11.56 12 27217 6419 90594799
Intestinal obstruction 11.85 11.56 31 27198 37100 90564118
Limb injury 11.84 11.56 28 27201 31480 90569738
Red blood cell sedimentation rate increased 11.81 11.56 5 27224 82590 90518628
Vertigo positional 11.74 11.56 9 27220 3335 90597883
Ear pain 11.64 11.56 41 27188 57661 90543557
Ventricular hypertrophy 11.63 11.56 9 27220 3382 90597836

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Echolalia 83.22 15.54 18 7141 371 42613805
Narcotic bowel syndrome 81.39 15.54 15 7144 130 42614046
Dizziness 62.02 15.54 132 7027 249122 42365054
Completed suicide 57.92 15.54 76 7083 96389 42517787
Renal fusion anomaly 48.23 15.54 9 7150 84 42614092
Vertigo 45.26 15.54 41 7118 34306 42579870
Congenital eye disorder 40.26 15.54 9 7150 217 42613959
Tachyphylaxis 37.65 15.54 8 7151 151 42614025
Epispadias 31.59 15.54 7 7152 162 42614014
Product name confusion 29.72 15.54 6 7153 87 42614089
Mental status changes 29.71 15.54 36 7123 42079 42572097
Hepatic ischaemia 29.22 15.54 8 7151 451 42613725
Fall 27.36 15.54 94 7065 234426 42379750
Hypertensive crisis 23.73 15.54 17 7142 10189 42603987
Pleurothotonus 21.58 15.54 8 7151 1203 42612973
Cerebrovascular accident 21.27 15.54 49 7110 97111 42517065
Nausea 20.50 15.54 125 7034 396674 42217502
Ventricular septal defect 19.45 15.54 11 7148 4388 42609788
Asthenia 17.46 15.54 93 7066 280700 42333476
Hypoacusis 16.58 15.54 18 7141 18684 42595492
Foetal exposure during pregnancy 16.52 15.54 29 7130 47282 42566894
Hallucination, auditory 16.23 15.54 16 7143 14848 42599328
Hyperreflexia 15.90 15.54 9 7150 3598 42610578

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Vertigo 172.57 12.36 152 26102 86718 110476327
Dizziness 130.06 12.36 412 25842 697781 109865264
Completed suicide 93.64 12.36 189 26065 242192 110320853
Fall 79.41 12.36 318 25936 603164 109959881
Echolalia 70.78 12.36 18 26236 533 110562512
Cerebrovascular accident 69.55 12.36 141 26113 181143 110381902
Narcotic bowel syndrome 66.41 12.36 15 26239 264 110562781
Drug ineffective 59.21 12.36 176 26078 1520364 109042681
Multiple sclerosis relapse 57.19 12.36 65 26189 50175 110512870
Urticaria thermal 47.40 12.36 13 26241 518 110562527
Administration site erythema 45.06 12.36 12 26242 427 110562618
Lower respiratory tract infection 43.09 12.36 4 26250 243102 110319943
Off label use 42.39 12.36 198 26056 1499987 109063058
Product dose omission issue 41.75 12.36 169 26085 321613 110241432
Hand deformity 40.37 12.36 3 26251 218503 110344542
Synovitis 40.36 12.36 8 26246 274084 110288961
Femoral neck fracture 39.95 12.36 29 26225 12538 110550507
General physical health deterioration 39.80 12.36 26 26228 425269 110137776
Pemphigus 39.49 12.36 3 26251 214567 110348478
Dysphoria 38.24 12.36 22 26232 6406 110556639
Contraindicated product administered 37.08 12.36 7 26247 248260 110314785
Transient ischaemic attack 34.94 12.36 58 26196 63924 110499121
Asthenia 34.34 12.36 280 25974 688719 109874326
Salivary gland calculus 34.33 12.36 9 26245 301 110562744
Urinary tract infection 33.66 12.36 160 26094 326122 110236923
Treatment failure 33.45 12.36 12 26242 277222 110285823
Pericarditis 33.10 12.36 6 26248 219108 110343937
Gait disturbance 32.85 12.36 142 26112 278066 110284979
Multiple sclerosis 32.26 12.36 35 26219 25663 110537382
Anti-cyclic citrullinated peptide antibody positive 32.23 12.36 3 26251 181981 110381064
Infusion related reaction 32.14 12.36 26 26228 381136 110181909
Appetite disorder 32.10 12.36 23 26231 9746 110553299
Nausea 31.73 12.36 439 25815 1235251 109327794
Pyrexia 31.31 12.36 109 26145 898156 109664889
Back pain 30.66 12.36 171 26083 370825 110192220
Febrile neutropenia 30.12 12.36 19 26235 316748 110246297
Coronary artery disease 28.95 12.36 57 26197 71633 110491412
Maternal exposure during pregnancy 27.56 12.36 13 26241 254870 110308175
Full blood count decreased 27.53 12.36 36 26218 32063 110530982
Balance disorder 27.50 12.36 75 26179 116485 110446560
Visual impairment 27.34 12.36 82 26172 134346 110428699
Headache 27.04 12.36 324 25930 882053 109680992
Hepatic enzyme increased 26.91 12.36 22 26232 320870 110242175
Tachyphylaxis 26.90 12.36 8 26246 427 110562618
Seizure 26.18 12.36 113 26141 221072 110341973
Glossodynia 26.12 12.36 10 26244 221994 110341051
Fatigue 26.11 12.36 419 25835 1215539 109347506
Systemic lupus erythematosus 25.96 12.36 14 26240 254324 110308721
Chest pain 25.67 12.36 165 26089 376210 110186835
Dizziness postural 23.99 12.36 23 26231 14586 110548459
Inflammation 23.93 12.36 8 26246 193230 110369815
Haemorrhagic diathesis 23.13 12.36 17 26237 7491 110555554
Liver injury 22.97 12.36 4 26250 150409 110412636
Myalgia 22.88 12.36 109 26145 222272 110340773
Vitamin B12 deficiency 22.81 12.36 19 26235 10036 110553009
Folliculitis 22.47 12.36 6 26248 167647 110395398
Product name confusion 22.20 12.36 6 26248 226 110562819
Arthritis infective 22.20 12.36 19 26235 10410 110552635
Mental status changes 22.12 12.36 53 26201 76069 110486976
Thinking abnormal 21.46 12.36 22 26232 15118 110547927
Rheumatoid factor positive 21.24 12.36 3 26251 131637 110431408
Feeling abnormal 21.13 12.36 92 26162 180619 110382426
C-reactive protein increased 20.81 12.36 13 26241 217906 110345139
Photophobia 20.71 12.36 28 26226 25743 110537302
Tremor 20.71 12.36 99 26155 202133 110360912
Oral pain 20.51 12.36 34 26220 37410 110525635
Illness 20.51 12.36 54 26200 82117 110480928
Neutropenia 20.43 12.36 36 26218 374584 110188461
Skin warm 20.12 12.36 17 26237 9153 110553892
Chills 20.03 12.36 94 26160 190486 110372559
Psoriatic arthropathy 19.83 12.36 11 26243 196750 110366295
Head injury 19.58 12.36 36 26218 42981 110520064
Meniere's disease 19.53 12.36 5 26249 152 110562893
Dehydration 19.33 12.36 123 26131 279388 110283657
Pigmentation disorder 19.09 12.36 15 26239 7296 110555749
Peripheral vascular disorder 19.03 12.36 16 26238 8560 110554485
Anxiety 18.66 12.36 143 26111 344935 110218110
Hepatic ischaemia 18.65 12.36 8 26246 1243 110561802
Inner ear disorder 18.56 12.36 7 26247 779 110562266
Rhinorrhoea 18.45 12.36 60 26194 102606 110460439
Nervousness 18.26 12.36 32 26222 36819 110526226
Drug intolerance 18.00 12.36 44 26210 406468 110156577
Cardiac failure congestive 17.75 12.36 77 26177 150923 110412122
Decerebrate posture 17.37 12.36 5 26249 238 110562807
Drug interaction 17.18 12.36 61 26193 500122 110062923
Impaired healing 17.10 12.36 13 26241 196704 110366341
Hallucination 17.09 12.36 58 26196 101374 110461671
Neck pain 17.01 12.36 66 26188 123064 110439981
Scratch 16.86 12.36 18 26236 12961 110550084
Lung disorder 16.83 12.36 11 26243 180036 110383009
Bursitis 16.76 12.36 5 26249 129913 110433132
Neck injury 16.63 12.36 10 26244 3158 110559887
Delusional disorder, persecutory type 16.26 12.36 6 26248 628 110562417
Arthropathy 16.25 12.36 27 26227 287495 110275550
Emotional distress 16.14 12.36 34 26220 44813 110518232
Thrombocytopenia 16.05 12.36 37 26217 348848 110214197
Multiple organ dysfunction syndrome 16.00 12.36 8 26246 151702 110411343
Skin disorder 15.98 12.36 33 26221 42880 110520165
Depression 15.78 12.36 129 26125 317206 110245839
Pancytopenia 15.63 12.36 16 26238 209597 110353448
Sialoadenitis 15.50 12.36 9 26245 2664 110560381
Constipation 15.46 12.36 141 26113 357645 110205400
Dyspnoea 15.35 12.36 357 25897 1106515 109456530
Influenza 15.34 12.36 80 26174 169021 110394024
Condition aggravated 15.24 12.36 107 26147 734729 109828316
Sneezing 14.85 12.36 27 26227 31957 110531088
Myocardial infarction 14.83 12.36 87 26167 191996 110371049
Lip dry 14.56 12.36 3 26251 100080 110462965
Multiple allergies 14.18 12.36 16 26238 12247 110550798
Migraine 14.08 12.36 79 26175 171573 110391472
Bronchitis 14.04 12.36 74 26180 156958 110406087
Deafness permanent 14.03 12.36 6 26248 925 110562120
Drug abuse 13.85 12.36 13 26241 177398 110385647
Sleep apnoea syndrome 13.79 12.36 30 26224 40417 110522628
Therapeutic product effect incomplete 13.61 12.36 20 26234 223785 110339260
Pleurothotonus 13.41 12.36 8 26246 2490 110560555
Unresponsive to stimuli 13.05 12.36 39 26215 63751 110499294
Liver disorder 12.88 12.36 9 26245 142234 110420811
Ill-defined disorder 12.84 12.36 11 26243 156842 110406203
Syncope 12.70 12.36 87 26167 202449 110360596
Hyperlipidaemia 12.69 12.36 27 26227 35821 110527224
Type 2 diabetes mellitus 12.69 12.36 14 26240 177218 110385827
Diverticulum 12.68 12.36 17 26237 15509 110547536
Haemorrhagic stroke 12.66 12.36 16 26238 13773 110549272
Tenderness 12.61 12.36 24 26230 29413 110533632

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R06AE05 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Piperazine derivatives
ATC R06AE55 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Piperazine derivatives
FDA PE N0000009034 Emesis Suppression
MeSH PA D000932 Antiemetics
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D006633 Histamine Antagonists
MeSH PA D006634 Histamine H1 Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018926 Anti-Allergic Agents
CHEBI has role CHEBI:35610 antineoplastic agent
FDA EPC N0000178372 Antiemetic
CHEBI has role CHEBI:50919 antiemetic

Related Drugs by ATC class:

R06AE Piperazine derivatives 6 drugs
buclizinecetirizinechlorcyclizinecyclizinelevocetirizineoxatomide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Prevention of motion sickness indication 37031009 DOID:2951
Motion sickness indication 37031009 DOID:2951
Vertigo indication 399153001
Chronic idiopathic constipation contraindication 82934008
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.34 Basic
pKa2 3.34 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Histamine H1 receptor GPCR ANTAGONIST CHEMBL CHEMBL
Nuclear receptor subfamily 1 group I member 3 Nuclear hormone receptor ANTAGONIST IC50 7.16 IUPHAR
Serine protease hepsin Enzyme IC50 5.70 CHEMBL
Constitutive androstane receptor Nuclear hormone receptor AGONIST EC50 7.60 IUPHAR

External reference:

IDSource
4019809 VUID
N0000147898 NUI
D01317 KEGG_DRUG
31884-77-2 SECONDARY_CAS_RN
4017843 VANDF
4019809 VANDF
CHEBI:6709 CHEBI
CHEMBL1623 ChEMBL_ID
CHEMBL3989555 ChEMBL_ID
DB00737 DRUGBANK_ID
6676 RXNORM
1696 MMSL
5029 MMSL
d00859 MMSL
003400 NDDF
004798 NDDF
372879002 SNOMEDCT_US
387243002 SNOMEDCT_US
84951002 SNOMEDCT_US
C0025039 UMLSCUI
D008468 MESH_DESCRIPTOR_UI
4034 PUBCHEM_CID
2757 IUPHAR_LIGAND_ID
204 INN_ID
3L5TQ84570 UNII
3L5TQ84570 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Wal-Dram 2 Quick-Dissolving HUMAN OTC DRUG LABEL 1 0363-1407 TABLET, ORALLY DISINTEGRATING 25 mg ORAL OTC Monograph Drug 14 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 0363-4040 TABLET, CHEWABLE 25 mg ORAL OTC Monograph Drug 15 sections
Meclizine Hydrochloride HUMAN OTC DRUG LABEL 1 0363-5172 TABLET, CHEWABLE 25 mg ORAL OTC Monograph Drug 16 sections
Meclizine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-1736 TABLET 25 mg ORAL ANDA 10 sections
MECLIZINE HUMAN OTC DRUG LABEL 1 0536-1297 TABLET 12.50 mg ORAL OTC Monograph Drug 12 sections
Meclizine Hydrochloride HUMAN OTC DRUG LABEL 1 0536-1299 TABLET, CHEWABLE 25 mg ORAL OTC Monograph Drug 17 sections
MECLIZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8514 TABLET 12.50 mg ORAL ANDA 23 sections
MECLIZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 0615-8515 TABLET 25 mg ORAL ANDA 23 sections
Meclizine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7375 TABLET 12.50 mg ORAL ANDA 23 sections
Meclizine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-7376 TABLET 25 mg ORAL ANDA 23 sections
PhysiciansCare Motion Sickness HUMAN OTC DRUG LABEL 1 0924-1008 TABLET 25 mg ORAL OTC Monograph Drug 15 sections
MECLIZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 10544-081 TABLET 25 mg ORAL ANDA 10 sections
Meclizine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-108 TABLET 25 mg ORAL ANDA 11 sections
Meclizine HCl HUMAN OTC DRUG LABEL 1 10544-249 TABLET 12.50 mg ORAL OTC monograph final 9 sections
Motion Sickness Relief HUMAN OTC DRUG LABEL 1 11673-356 TABLET 25 mg ORAL OTC Monograph Drug 15 sections
Less Drowsy Motion Sickness Relief HUMAN OTC DRUG LABEL 1 11822-0775 TABLET 25 mg ORAL OTC Monograph Drug 15 sections
Rugby Travel SicknessMeclizine HCl, 25 mg Each (ANTIEMETIC) HUMAN OTC DRUG LABEL 1 12634-246 TABLET, CHEWABLE 25 mg ORAL OTC monograph final 15 sections
Meclizine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 12634-424 TABLET 25 mg ORAL ANDA 11 sections
Meclizine HCl HUMAN OTC DRUG LABEL 1 13811-646 TABLET 12.50 mg ORAL OTC monograph final 13 sections
Meclizine HCl HUMAN OTC DRUG LABEL 1 13811-647 TABLET 25 mg ORAL OTC monograph final 13 sections
Meclizine HCl HUMAN OTC DRUG LABEL 1 13811-648 TABLET, CHEWABLE 25 mg ORAL OTC monograph final 13 sections
MECLIZINE HUMAN OTC DRUG LABEL 1 16103-386 TABLET 12.50 mg ORAL OTC Monograph Drug 12 sections
MECLIZINE HUMAN OTC DRUG LABEL 1 16103-387 TABLET, CHEWABLE 25 mg ORAL OTC Monograph Drug 12 sections
Meclizine Hydrochloride Human Prescription Drug Label 1 16571-660 TABLET 12.50 mg ORAL NDA AUTHORIZED GENERIC 25 sections
Meclizine Hydrochloride Human Prescription Drug Label 1 16571-661 TABLET 25 mg ORAL NDA AUTHORIZED GENERIC 25 sections
Meclizine Hydrochloride Human Prescription Drug Label 1 16571-662 TABLET 50 mg ORAL NDA AUTHORIZED GENERIC 25 sections
Meclizine Hydrochloride Human Prescription Drug Label 1 16571-663 TABLET, CHEWABLE 25 mg ORAL NDA AUTHORIZED GENERIC 25 sections
Meclizine HCl HUMAN OTC DRUG LABEL 1 16571-824 TABLET, CHEWABLE 25 mg ORAL OTC Monograph Drug 14 sections
MECLIZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-146 TABLET 25 mg ORAL ANDA 10 sections
MECLIZINE HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 16590-301 TABLET 12.50 mg ORAL ANDA 10 sections